糖尿病設備和治療市場（按類別、疾病類型和地區）

Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2025年06月12日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

糖尿病設備和治療市場預計在 2025 年達到 1,916.6 億美元，預計到 2032 年將達到 3,734.9 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 10.0%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	1916.6億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年	10.00%	2032年價值預測	3734.9億美元

糖尿病設備和藥物是指專門為幫助管理和治療糖尿病（一種以高血糖為特徵的慢性代謝性疾病）而設計的工具和藥物。這些設備和藥物在監測血糖值、注射胰島素以及控制糖尿病相關症狀和併發症發揮著至關重要的作用。血糖儀、連續血糖監測系統、胰島素幫浦、胰島素筆等都是幫助管理糖尿病的裝置的例子。同時，藥物包括胰島素、Metformin、磺醯尿素類和Amylin。這些設備和藥物對於糖尿病患者監測血糖值、注射胰島素和有效管理病情至關重要，從而降低併發症風險並促進整體健康。

市場動態

全球糖尿病盛行率持續上升，主要原因是久坐不動的生活方式、不健康的飲食以及肥胖率上升等因素。糖尿病患者的激增帶來了對有效監測和治療糖尿病的設備和藥物的巨大需求。在設備方面，持續血糖監測系統已廣受歡迎。例如，2022年3月，全球領先的糖尿病患者即時持續血糖監測公司DexCom宣布，Dexcom G7持續血糖監測 (CGM) 系統已獲得CE標誌（歐洲合格認證），可供2歲及以上糖尿病患者（包括孕婦）在歐洲使用。

糖尿病治療市場也取得了顯著發展。口服降血糖藥物和胰島素注射等傳統療法仍佔市場主導地位。然而，人們越來越重視新型藥物的開發，例如基於腸促胰島素的促效劑、鈉葡萄糖協同轉運蛋白-2 (SGLT-2) 抑制劑以及（Glucagon-Like Peptide-1 ）GLP-1受體激動劑。這些創新藥物療效更佳，副作用更少，為患者帶來了更多便利。

研究的主要特點

本報告對全球糖尿病設備和治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球糖尿病設備和藥品市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過分析全球糖尿病設備和治療市場所使用的各種策略矩陣來促進決策。

介紹
北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 東南亞國協
- 澳洲
- 韓國
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
非洲
- 北非
- 中部非洲
- 南非

第7章競爭態勢

公司簡介
Abbott Laboratories
Bristol-Myers Squibb
DexCom, Inc.
Eli Lilly and Company
Companion Medical
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin Ltd.
F. Hoffmann-La Roche AG
DreaMed Diabetes
Hua Medicine
Sanofi

第 8 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI3857

Diabetes Devices And Drugs Market is estimated to be valued at USD 191.66 Bn in 2025 and is expected to reach USD 373.49 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 191.66 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.00%	2032 Value Projection:	USD 373.49 Bn

Diabetes devices and drugs refer to the tools and medications specifically designed to help individuals manage and treat diabetes, a chronic metabolic disorder characterized by high blood sugar levels. These devices and drugs play a crucial role in monitoring blood glucose levels, delivering insulin, and controlling the symptoms and complications associated with diabetes. Glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, etc. are a few examples of devices that aid the management of diabetes. Whereas, drugs include insulin, metformin, sulfonylureas, amylin analogues, etc. These devices and drugs are essential for individuals with diabetes to monitor their blood sugar levels, administer insulin, and manage the condition effectively, thereby reducing the risk of complications and promoting overall well-being.

Market Dynamics

The global prevalence of diabetes has been rising steadily primarily driven by the factors such as sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates. This surge in the diabetic population has created a substantial demand for effective devices and drugs to monitor and treat the condition. In terms of devices, continuous glucose monitoring systems have gained significant popularity. For instance, in March 2022, DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System received CE Mark (Conformite Europeenne) for people with diabetes in Europe aged 2 and above, including pregnant women.

The market for diabetes drugs has also witnessed remarkable advancements. Traditional treatments, such as oral antidiabetic drugs and insulin injections, continue to dominate the market. However, there has been a growing emphasis on the development of novel drugs, including incretin-based therapies, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, and (Glucagon-like Peptide-1) GLP-1 receptor agonists. These innovative medications offer improved efficacy and reduced side effects, and enhanced convenience for patients.

Key features of the study

This report provides an in-depth analysis of the global diabetes devices and drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global diabetes devices and drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global diabetes devices and drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetes devices and drugs market

Market Segmentation

Global Diabetes Devices and Drugs Market, By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Other Testing Devices
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
Global Diabetes Devices and Drugs Market, By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
Global Diabetes Devices and Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Abbott Laboratories
- Bristol-Myers Squibb
- DexCom
- Eli Lilly and Company
- Companion Medical
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Johnson & Johnson
- Lupin Ltd.
- F.Hoffmann-La Roche AG
- DreaMed Diabetes
- Hua Medicine
- Sanofi

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Category
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Pipeline Analysis

4. Global Diabetes Devices and Drugs Market, By Category, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Diagnosis and Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Segment Trends
  - Blood Glucose Monitoring Devices
  - Software Programs for Diabetes Monitoring
  - Artificial Pancreas
  - Other Testing Devices
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Segment Trends
  - Insulin
  - Insulin Delivery
  - Oral Hypoglycemic Agents
  - Cell Therapies

5. Global Diabetes Devices and Drugs Market, By Disease Type, 2020 - 2032 (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Billion)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Billion)

6. Global Diabetes Devices and Drugs Market, By Region, 2020 - 2032, (US$ Billion)

Overview
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DexCom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Companion Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
DreaMed Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hua Medicine
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies